Hybio Pharmaceutical Co., Ltd. Class A

Hybio Pharmaceutical Co., Ltd. Class A

SSZSE:300199
22.20
CNY
+0.17
(+0.77%)
0.45EPS
53.02P/E
21.13BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A carries a market capitalization of 21.13B, placing it among publicly traded companies globally. Its enterprise value stands at 22.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap21.13B
Enterprise Value22.94B

Important Dates

Hybio Pharmaceutical Co., Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A has 883.24M shares outstanding.

Shares Outstanding883.24M

Valuation Ratios

As of September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 53.02. The price-to-sales ratio is 13.96, and the price-to-book ratio stands at 19.72.

PE Ratio53.02
PS Ratio13.96
PB Ratio19.72
P/TBV Ratio33.08

Enterprise Valuation

As of September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A trades at an EV/EBITDA multiple of 52.41 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 15.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 52.41 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 22.94B versus a market cap of 21.13B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales15.03
EV / EBITDA52.41
EV / EBIT52.41

Financial Position

As of September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A maintains a current ratio of 0.62, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 184.29, indicating elevated leverage, while an interest coverage ratio of 5.10 demonstrates adequate ability to service its debt obligations.

Current Ratio0.62
Quick Ratio0.11
Debt / Equity184.29
Debt / EBITDA4.57
Interest Coverage5.10

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A posted a return on equity (ROE) of 44.77, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 13.52 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.98, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 16.40, useful for judging operating efficiency across full business cycles. The company generates approximately 1.24M in revenue per employee across its workforce of 1,226.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.50 indicates how many times Hybio Pharmaceutical Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)44.77
Return on Assets (ROA)10.98
Return on Invested Capital (ROIC)13.52
Return on Capital Employed (ROCE)16.40
Revenue Per Employee1.24M
Employee Count1,226.00
Inventory Turnover1.50

Taxes

CNY

Over the twelve months ended September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A recorded 38.42M in income tax expense. That works out to an effective tax rate of 8.77, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 437.87M, leaving 401.86M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax38.42M
Effective Tax Rate8.77

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hybio Pharmaceutical Co., Ltd. Class A's stock has gained approximately 14.43% over the past 52 weeks. The 50-day moving average sits at 23.64, while the 200-day moving average is 21.88.

52-Week Price Change14.43%
50-Day Moving Average23.64
200-Day Moving Average21.88

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A generated 1.53B in revenue and converted that into 401.86M in net income, yielding earnings per share of 0.45. EBITDA reached 437.60M, while operating income came in at 537.52M.

Revenue1.53B
Gross Profit960.42M
Operating Income537.52M
Pretax Income437.87M
Net Income401.86M
EBITDA437.60M
EBIT437.60M
Earnings Per Share (EPS)0.45

Balance Sheet

CNY

As of September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A holds 205.63M in cash and equivalents against 2.00B in total debt, resulting in a net debt position of 1.66B. Total book value stands at 1.07B, with working capital of -681.19M providing operational flexibility.

Cash & Cash Equivalents205.63M
Total Debt2.00B
Net Debt1.66B
Equity (Book Value)1.07B
Book Value Per Share1.21
Working Capital-681.19M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-326.79M

Margins

Over the twelve months ended September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A posted a gross margin of 62.95, reflecting its pricing power and cost economics. The operating margin of 35.23 and net profit margin of 26.34 provide insight into operational efficiency.

Gross Margin62.95
Operating Margin35.23
Pretax Margin28.70
Profit Margin26.34
EBITDA Margin28.68

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A paid dividends of 0.11 per share. The dividend payout ratio of 24.53 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.05, meaning Hybio Pharmaceutical Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.11
Payout Ratio24.53
Shareholder Yield-0.05

Stock Splits

Hybio Pharmaceutical Co., Ltd. Class A's most recent stock split took place on April 14, 2015 with a 1:2 split ratio.

Last Split Date4/14/2015
Split Ratio1:2

Scores

As of September 30, 2026, Hybio Pharmaceutical Co., Ltd. Class A has an Altman Z-Score of 4.59, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score4.59